0 CHECKOUT

Pancreatic Cancer Drug Pipeline Update

  • ID: 1196704
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

There are today 385 companies plus partners developing 444 drugs targeting pancreatic cancer in development. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 136 drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 352 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 340 out of the 343 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 74 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators
Includes more than 385 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Novartis AG
  • Pfizer Inc.
  • Gilead Sciences Inc
  • Aduro Biotech Inc.
  • Celgene Corporation
  • Halozyme Inc.